School of Pharmacy, Shenyang Pharmaceutical University, 103Wenhua Road, Shenyang, 110016, Liaoning Province, China.
Pharm Res. 2020 Nov 13;37(12):242. doi: 10.1007/s11095-020-02811-1.
In order to improve the therapeutic efficiency of the chemotherapeutic drug paclitaxel in tumors, a folate-based Paclitaxel nanoemulsion (FNEs) was developed for tumor targeted treatment.
In this study, we designed a folate-targeted nanoemulsion (folate/PEG-DSPE/nanoemulsion, FNEs) based on the traditional nanoemulsion using the principle of long-circulation targeting receptor mediated. The nanoemulsion (folate/PEG-DSPE/nanoemulsion, FNEs) was fabricated using high-pressure homogenization with a microfluidizer.
The nanoemulsion (folate/PEG-DSPE/nanoemulsion, FNEs) can improve the delivery efficiency of nanocarriers at the tumor site by virtue of the high expression of folate receptors on the tumor surface. Malvern Nanoseries device and transmission electron microscopy (TEM) analyses showed that the nanoemulsions were spherical with an average diameter of 140 nm. The nanoemulsions can effectively carry paclitaxel (PTX) with an encapsulation rate of about 95%. And in vitro experiments have shown that it can efficiently increase the uptake of PTX in 4 T1 breast cancer cells and FNEs had a targeting capability hundredfold higher than that of PTX-loaded nanoemulsions (PTX-NEs) without folate. In vivo experiments have shown that the pharmacokinetic parameters of FNEs were better than those of other PTX groups and FNEs can significantly enhance circulation time in the body of the subcutaneously implanted 4 T1 breast cancer in mice, increase the accumulation of chemotherapy drugs at tumor sites and effectively inhibit tumor growth with lower system toxicity.
This study can effectively improve the therapeutic efficiency of chemotherapy drugs for tumors, and provide an useful reference for solving the problem of low efficacy of chemotherapy drugs in clinical treatment of tumors. Graphical Abstract Schematic representation of Folic acid/PEG-DSPE/nano-emulsion (FNEs) specifically target tumor cells and enhanced anti-tumor effects.
为了提高化疗药物紫杉醇在肿瘤中的治疗效果,开发了一种基于叶酸的紫杉醇纳米乳剂(FNEs)用于肿瘤靶向治疗。
在这项研究中,我们基于传统的纳米乳剂,利用长循环靶向受体介导的原理设计了一种叶酸靶向纳米乳剂(叶酸/PEG-DSPE/纳米乳剂,FNEs)。纳米乳剂(叶酸/PEG-DSPE/纳米乳剂,FNEs)是通过高压匀质法与微流控仪制备的。
纳米乳剂(叶酸/PEG-DSPE/纳米乳剂,FNEs)可以通过肿瘤表面叶酸受体的高表达来提高纳米载体在肿瘤部位的递药效率。马尔文纳米系列装置和透射电子显微镜(TEM)分析表明,纳米乳剂呈球形,平均直径为 140nm。纳米乳剂可以有效地携带紫杉醇(PTX),包封率约为 95%。体外实验表明,它可以有效地增加 4T1 乳腺癌细胞中 PTX 的摄取,并且 FNEs 比没有叶酸的载有 PTX 的纳米乳剂(PTX-NEs)具有高 100 倍的靶向能力。体内实验表明,FNEs 的药代动力学参数优于其他 PTX 组,并且 FNEs 可以显著延长皮下植入的 4T1 乳腺癌小鼠体内的循环时间,增加化疗药物在肿瘤部位的积累,并有效抑制肿瘤生长,同时降低系统毒性。
本研究可以有效地提高化疗药物对肿瘤的治疗效果,为解决临床治疗肿瘤中化疗药物疗效低的问题提供了有益的参考。